Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its drug candidate, 177LuLNC1010. This investigational therapy is a somatostatin receptor 2 (SSTR2) targeted radioactive drug designed for the treatment of gastrointestinal pancreatic neuroendocrine tumors (GEP NETs).
The only globally available SSTR2 targeted radioactive drug is currently Novartis’s Lutathera (lutetium Lu 177 dotatate) from Swiss pharmaceutical giant Novartis. However, 177Lu-LNC1010 promises to enhance upon the benefits of targeted therapy. With a patented chemical structure, it aims to improve the pharmacokinetic and pharmacological properties of the probe. This enhancement will increase the effective uptake of drugs by tumors, extend the treatment time window, and reduce the dosage of radioactive nuclides, potentially offering the same or better treatment outcomes at a lower cost to patients.- Flcube.com
